Josh Muntner

Josh Muntner joined Imvax as Chief Financial Officer in August 2021, and he has more than 20 years of experience in healthcare investment banking and corporate finance, providing strong expertise in areas of capital markets and fundraising. He has also played a lead role in a wide range of healthcare-related transactions. He most recently served as Chief Financial Officer at Mesoblast Limited (NASDAQ: MESO), a late-stage biotechnology company. Earlier in his career, Mr. Muntner held the position of Senior Vice President of Business Development at ContraFect Corporation (NASDAQ: CFRX), a clinical-stage biotechnology company, and served as Managing Director and Co-Head of Healthcare Investment Banking at Janney Montgomery Scott. Prior to this, he worked at Oppenheimer & Co. and its U.S. predecessor, CIBC World Markets.

Mr. Muntner holds a B.A. from Carnegie Mellon University and an MBA from the Anderson School of Management at the University of California, Los Angeles.